secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2026-06-25T21:08:23+00:00
Accession:  0001193125-26-283033
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero shareholders approve doubling authorized shares to 240M and 2026 equity plan
--------------------------------------------------------------------------------

- Authorized common shares increased from 120M to 240M via certificate of amendment filed June 23, 2026.
- 2026 Stock Incentive Plan approved; up to 12,895,866 shares may be issued under the plan.
- Directors Milind Deshpande, Ph.D. and Kathleen Tregoning reelected as Class III directors until 2029.
- PricewaterhouseCoopers LLP ratified as independent auditor for fiscal year 2026 with 99.5% votes for.
- Advisory vote on named executive officer compensation approved with ~96% of votes cast in favor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312526283033/0001193125-26-283033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312526283033/d86736d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-283033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer